BTP Kria Resources Ltd Com Npv

Paladin labs Inc. (TSX:PLB), a leading Canadian specialty Pharmaceutical
company, announced today the launch of Abstral(R) (fentanyl citrate sublingual
tablet). Abstral(R) is a novel, rapidly-disintegrating, sublingual (under the
tongue) formulation of fentanyl, a well-established opioid used for the
management of breakthrough pain for cancer patients already receiving, and
tolerant to opioid analgesics for chronic pain. Abstral(R) will complement
Paladin's growing pain franchise which includes Tridural(R), Metadol(R) and
Pennsaid(R). 


"Though officially launching today, Abstral(R) has been available to patients
and their physicians in Canada for almost 2 months under our compassionate early
use program", said Jonathan Ross Goodman, President and CEO of Paladin Labs.
"This early experience program with Abstral(R) has seen meaningful and
heart-warming quality of life improvements in many patients taking our product.
The importance of this quality of life improvement to patients, their families
and care givers should not be underestimated and gives us confidence as we now
transition into the full commercial launch phase of this important new product."



Paladin obtained the Canadian rights from ProStrakan Group plc ("ProStrakan"), a
wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., (TSE:4151) in December
2008 and was granted Canadian regulatory approval in February 2011.


About Abstral(R) 

Abstral(R) is a fast-acting and rapidly disintegrating tablet for sublingual
administration of fentanyl intended for the management of breakthrough pain in
cancer patients who are already receiving, and tolerant to opioid analgesics for
their underlying persistent cancer pain. 


Abstral(R) is already marketed by ProStrakan across the principal European
markets. In the top four European markets, Abstral(R) achieved a 24% market
share by tablet volume of short-acting fentanyl products (Source: IMS data June
2010). 


About Breakthrough Cancer Pain 

Breakthrough cancer pain ("BTP") is defined as rapid onset and short duration
exacerbations of severe pain experienced by patients who have relatively stable
and adequately controlled baseline pain.(1) It is known as BTP because it
"breaks through" a regular pain medicine schedule. For some patients, BTP occurs
during certain everyday activities, such as walking or dressing. For others, it
occurs unexpectedly without any apparent cause. Between 64% to 89% of patients
with cancer experience BTP and they average 4 to 7 episodes per day. (2) 


In a recent survey of patients with cancer related BTP(3): 

89% stated that BTP negatively affected their quality of life 

73% stated that BTP wakes them from a deep sleep at least once a month 

76% stated that BTP affects their ability to perform everyday household chores 

75% stated that BTP is one of the most challenging effects of having cancer 

35% stated that BTP affects their relationships with their family members 

82% stated that BTP negatively affects their emotional health 

About Paladin Labs Inc. 

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian market. With this strategy, a focused
national sales team and proven marketing expertise, Paladin has evolved into one
of Canada's leading specialty pharmaceutical companies. Paladin's shares trade
on the Toronto Stock Exchange under the symbol PLB. For more information about
Paladin, please visit the Company's web site at www.paladinlabs.com.


This press release may contain forward-looking statements and predictions. These
forward-looking statements, by their nature, necessarily involve risks and
uncertainties that could cause actual results to differ materially from those
contemplated by the forward-looking statements. The Company considers the
assumptions on which these forward-looking statements are based to be reasonable
at the time they were prepared, but cautions that these assumptions regarding
the future events, many of which are beyond the control of the Company and its
subsidiary, may ultimately prove to be incorrect. Factors and risks, which could
cause actual results to differ materially from current expectations, are
discussed in the annual report as well as in the Company's Annual Information
Form for the year ended December 31, 2010. The Company disclaims any intention
or obligation to update or revise any forward-looking statements whether as a
result of new information or future events and except as required by law. For
additional information on risks and uncertainties relating to these
forward-looking statements, investors should consult the Company's ongoing
quarterly fillings, annual report and Annual Information Form and other fillings
found on SEDAR at www.sedar.com. 


(1) Portenoy RK, Hagen NA. Pain 1990; 41: 273-281

(2) Portenoy RK et al. Pain 1999; 81(1-2):129-134

(3) The American Pain Foundation. Breakthrough Cancer Pain Survey Fact Sheet

Kria Resources Ltd Com Npv (TSXV:BTP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Kria Resources Ltd Com Npv (TSXV:BTP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024